Literature DB >> 16221846

Neuregulin-1 reverses long-term potentiation at CA1 hippocampal synapses.

Oh-Bin Kwon1, Marines Longart, Detlef Vullhorst, Dax A Hoffman, Andres Buonanno.   

Abstract

Neuregulin-1 (NRG-1) has been identified genetically as a schizophrenia susceptibility gene, but its function in the adult brain is unknown. Here, we show that NRG-1beta does not affect basal synaptic transmission but reverses long-term potentiation (LTP) at hippocampal Schaffer collateral-->CA1 synapses in an activity- and time-dependent manner. Depotentiation by NRG-1beta is blocked by two structurally distinct and selective ErbB receptor tyrosine kinase inhibitors. Moreover, ErbB receptor inhibition increases LTP at potentiated synapses and blocks LTP reversal by theta-pulse stimuli. NRG-1beta selectively reduces AMPA, not NMDA, receptor EPSCs and has no effect on paired-pulse facilitation ratios. Live imaging of hippocampal neurons transfected with receptors fused to superecliptic green fluorescent protein, as well as quantitative analysis of native receptors, show that NRG-1beta stimulates the internalization of surface glutamate receptor 1-containing AMPA receptors. This novel regulation of LTP by NRG-1 has important implications for the modulation of synaptic homeostasis and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221846      PMCID: PMC6725708          DOI: 10.1523/JNEUROSCI.2100-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  88 in total

Review 1.  Genetic architecture of declarative memory: implications for complex illnesses.

Authors:  Carrie E Bearden; Katherine H Karlsgodt; Peter Bachman; Theo G M van Erp; Anderson M Winkler; David C Glahn
Journal:  Neuroscientist       Date:  2011-08-10       Impact factor: 7.519

Review 2.  Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders.

Authors:  Sacha B Nelson; Vera Valakh
Journal:  Neuron       Date:  2015-08-19       Impact factor: 17.173

Review 3.  Pharmacological therapies for Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird
Journal:  Wien Med Wochenschr       Date:  2016-01-12

4.  Neuregulin directly decreases voltage-gated sodium current in hippocampal ErbB4-expressing interneurons.

Authors:  Megan J Janssen; Elias Leiva-Salcedo; Andres Buonanno
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

Review 5.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

6.  Disruption of hippocampal neuregulin 1-ErbB4 signaling contributes to the hippocampus-dependent cognitive impairment induced by isoflurane in aged mice.

Authors:  Xiao-Min Li; Fan Su; Mu-Huo Ji; Guang-Fen Zhang; Li-Li Qiu; Min Jia; Jun Gao; Zhongcong Xie; Jian-Jun Yang
Journal:  Anesthesiology       Date:  2014-07       Impact factor: 7.892

7.  Neuregulin-1 impairs the long-term depression of hippocampal inhibitory synapses by facilitating the degradation of endocannabinoid 2-AG.

Authors:  Huizhi Du; In-Kiu Kwon; Jimok Kim
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

8.  Localization and signaling of the receptor protein tyrosine kinase Tyro3 in cortical and hippocampal neurons.

Authors:  A L Prieto; S O'Dell; B Varnum; C Lai
Journal:  Neuroscience       Date:  2007-09-26       Impact factor: 3.590

9.  Regulation of glutamate receptor trafficking by leptin.

Authors:  Peter R Moult; Jenni Harvey
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

10.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Authors:  Lei Wen; Yi-Sheng Lu; Xin-Hong Zhu; Xiao-Ming Li; Ran-Sook Woo; Yong-Jun Chen; Dong-Min Yin; Cary Lai; Alvin V Terry; Almira Vazdarjanova; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.